BPNSs are loaded with the anticancer antibiotic adriamycin (DOX) and coupled with NH2-PEG-FA for tumor-targeted delivery. Most BP-based nanoformulations are used for synergistic photothermal therapy and heat-triggered DOX antitumor therapy, and BPNSs can be gradually degraded to phosphates/phosphonates, which enhances tissue repair through activation of ERK1/2 and PI3K/Akt pathways. The gene discussed is AKT1; the disease is neoplasm.